Evaluation of Efficacy of Ophthalmic Solution in Seasonal Allergic Conjunctivitis

Last updated: September 26, 2011
Sponsor: Vistakon Pharmaceuticals
Overall Status: Completed

Phase

3

Condition

Eye Disorders/infections

Allergies & Asthma

Allergy

Treatment

N/A

Clinical Study ID

NCT00364091
06-003-09
  • Ages > 10
  • All Genders

Study Summary

The purpose of this summary is to evaluate the efficacy and safety of R89674 0.025% ophthalmic solution compared with placebo or an active control in subjects with seasonal allergic conjunctivitis

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • history of positive diagnostic test for ragweed within the past 2 years;

  • positive bilateral response to ragweed as induced by conjunctival allergen challenge

Exclusion

Exclusion Criteria:

  • ocular infection;

  • history of retinal detachment, diabetic neuropathy, or any progressive retinaldisease;

  • moderate to severe asthma;

  • dry eye syndrome;

  • history of severe, unstable, or uncontrolled cardiovascular, pulmonary, hepatic, renalor autoimmune disease;

  • pregnancy or lactation

Study Design

Total Participants: 365
Study Start date:
August 01, 2006
Estimated Completion Date:

Connect with a study center

  • Louisville, Kentucky
    United States

    Site Not Available

  • North Andover, Massachusetts
    United States

    Site Not Available

  • Creve Coeur, Missouri
    United States

    Site Not Available

  • Charlotte, North Carolina
    United States

    Site Not Available

  • Philadelphia, Pennsylvania
    United States

    Site Not Available

  • Memphis, Tennessee
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.